HLB Biostep Subsidiary Croen Changes Name to HLB Biocode

Kroen announced on the 9th that it will change its company name to 'HLB BioCode.'

With HLB BioStep recently acquiring Kroen, the HLB Group is expanding its service scope from efficacy non-clinical CRO to GLP-certified toxicology non-clinical CRO. This enables the provision of a one-stop service throughout the entire non-clinical process. HLB BioStep is the largest efficacy non-clinical CRO in Korea. HLB BioCode is a toxicology testing specialized non-clinical CRO holding GLP certifications for 20 test items from government agencies such as the Ministry of Food and Drug Safety and the Ministry of Environment.

The new company name combines the first two letters of Cooperation and Development. It embodies the philosophy of dedicating to clients' new drug development and growing together.

Moon Jeong-hwan, CEO of HLB BioStep, decided to concurrently serve as CEO of HLB BioCode through the HLB BioCode board of directors. This is a strategic move to streamline customer sales and service operations, enable rapid decision-making on key issues, and realize responsible management.

CEO Moon said, "We can provide one-stop, full-cycle services for non-clinical trials," adding, "The service scope, which was previously limited to efficacy non-clinical, has greatly expanded, giving us overwhelming competitiveness."

HLB BioStep will participate jointly with HLB Group affiliates at ‘BIO USA’ held next month in San Diego, California, USA. As they can now provide both efficacy and toxicology non-clinical services, this will be the first step toward expanding into the global market. Since HLB BioCode has also joined as a subsidiary of HLB BioStep, they plan to implement specialized and extensive services in the non-clinical field through additional GLP certifications.

This content was produced with the assistance of AI translation services.